Insider buying is widely considered a positive indicator for any company. This holds truer for biotechnology companies because valuations are linked to pipeline candidates. The insiders have the most information about the progress of these candidates along with other vital information about the company.
However, insider buying can also mislead investors into making investments at inopportune moments. Therefore, it is important to view insiders buys in combination with other fundamental more »
On Feb. 28, a few minutes before closing, a single research paper sent Intuitive Surgical (NASDAQ: ISRG) tanking from the $570ish range to under $500. The widely circulated paper concluded that overall outcomes in hysterectomies using Intuitive's Da Vinci robot were no better than laparoscopic surgery -- and that the robot option was more expensive. Read the paper here. Critics of the paper say its authors did not consider faster more »
Last Friday, Piper Jaffray analysts speculated MAKO Surgical (NASDAQ: MAKO) would pre-announce selected earnings on January 7, 2013, urging investors at the time to buy shares of the robotic surgery specialist ahead of the news.
After all, they reasoned, if MAKO were to report in-line results of 3100 procedures and 16 RIO systems sold, it would "ease investor concerns and drive the stock significantly higher."
Horseshoes and hand grenades
Sure more »
To Brian's credit, he acknowledged the risk in stepping away from the beaten-down company, writing "now could be just the right time to be buying into MAKO Surgical." Given the company's less-than-stellar track record of accurately predicting sales, he's more »
Four weeks ago, I wondered in print whether MAKO Surgical's (NASDAQ: MAKO) third quarter results represented a breaking point for the company. With MAKO's after-the-bell announcement yesterday, it's time to touch base to see how it fared.
Third quarter revenue rose 46% from the same year-ago period to $29.2 million, with a net loss of $6.6 million, or 15 cents per share. Perhaps most importantly more »
Mark your calendars Fools! MAKO Surgical (NASDAQ: MAKO) is scheduled to announce Q3 2012 earnings on November 5, and I can almost sense a palpable increase in nervous ticks from frustrated long investors everywhere.
To that end, can you blame them? Anyone who bought MAKO shares four months ago is down to the tune of nearly 40%. If you pulled the trigger six months ago, you've endured an even more »
About a month ago I added three health care stocks to the watch list of my paper trading portfolio that I call the “No Drip, No Mess” Portfolio. One of the benefits of having a watch list is to pay a bit closer attention to companies that might one day be a good portfolio fit. You get to take a bit of an unbiased look at each company and are more »